Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04740476
Recruitment Status : Enrolling by invitation
First Posted : February 5, 2021
Last Update Posted : February 10, 2023
Information provided by (Responsible Party):
Stoke Therapeutics, Inc

Brief Summary:
Stoke Therapeutics is evaluating the long-term safety & tolerability of repeated doses of STK-001 in patients with Dravet syndrome who previously participated in studies of STK-001. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

Condition or disease Intervention/treatment Phase
Dravet Syndrome Drug: STK-001 Phase 2

Detailed Description:

This study is a multi-center, open-label, multiple-dose, safety extension study for patients who have completed another study of STK-001 and meet study eligibility criteria. STK-001 is an investigational new medicine for the treatment of Dravet syndrome. STK-001 is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).

STK-001 is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001
Actual Study Start Date : January 21, 2021
Estimated Primary Completion Date : February 3, 2026
Estimated Study Completion Date : March 3, 2027

Arm Intervention/treatment
Experimental: STK-001 multiple dose levels
Enrollment of patients after completion of study STK-001-DS-101 if eligible for additional dosing in this extension study. Patients will receive IT administration of study drug STK-001 at the dose level they received while participating in Study STK-001-DS-101, or at a dose level recommended by the Safety Monitoring Committee (SMC).The highest dose administered in this study may not exceed that which has already been evaluated in an STK-001 Phase 1/2 study, and doses above 30 mg/dose in this study require approval from the Food and Drug Administration (FDA). Patients will initially receive 3 doses, one every approximately 4 months (16 weeks). Patients who are tolerating treatment may continue treatment with doses approximately every 4 months, with an End of Study/Follow-up Visit 24 weeks after the last dose of study drug. Patients who do not continue treatment after the third dose will have a Follow-up Visit (V5) at Week 48 and an End of Study Visit at Week 56.
Drug: STK-001
STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.

Primary Outcome Measures :
  1. Safety of multiple doses of STK-001 [ Time Frame: Screening (Day -1) until 6 months after multiple drug dosing ]
    Safety variables for analysis include the incidence, type, severity, and seriousness of AEs, and changes in vital signs, ECG, laboratory, immunogenicity, physical examination, and Gillette FAQ parameters.

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) Parameters [ Time Frame: Dosing (Day 1) until 6 months after multiple drug dosing ]
    Analysis of plasma concentrations of STK-001

  2. Exposure of STK-001 in Cerebrospinal Fluid (CSF) [ Time Frame: Dosing (Day 1) until Week 32 (last study drug dosing day) ]
    Measurement of STK-001 concentrations

  3. Measurement of Seizure Frequency [ Time Frame: Screening (Day -1) until 6 months after multiple drug dosing ]
    Measurement of Seizure Frequency (by paper diary)

  4. Change in overall clinical status [ Time Frame: Screening (Day -1) until 6 months after multiple drug dosing ]
    Change in overall clinical status as measured by the Clinical Global Impression of Change (CGIC) and the Caregiver Global Impression of Change (CaGIC)

  5. Change in Quality of Life [ Time Frame: Screening (Day -1) until 6 months after multiple drug dosing ]
    Change in quality of life as measured by the EuroQoL-five dimensions, youth version (EQ-5D-Y) instrument

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed dosing with STK-001 and the End of Study Visit in Study STK-001-DS-101, with an acceptable safety profile per Investigator judgment.
  • Had satisfactory compliance with study visits and procedures in Study STK-001-DS-101 per Investigator and Sponsor judgment.
  • Completed Study STK-001-DS-101 within 4 weeks of the start of their participation in Study STK-001-DS-501 unless approved by sponsor.

Exclusion Criteria:

  • Met any withdrawal criteria from Study STK-001-DS-101.
  • Currently treated with an antiepileptic drug (AED) acting primarily as a sodium channel blocker, as maintenance therapy, including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide.
  • Clinically significant unstable medical conditions other than epilepsy.
  • Clinically relevant symptoms or a clinically significant illness (in the judgment of the Investigator) at Screening or prior to dosing on Day 1, other than epilepsy.
  • Spinal deformity or other condition that may alter the free flow of CSF or has an implanted CSF drainage shunt.
  • Treated (or is being treated) with an investigational product (other than STK-001) since participating in Study STK-001-DS-101.
  • Participating in an observational study, they are excluded unless approved by the Sponsor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04740476

Show Show 17 study locations
Sponsors and Collaborators
Stoke Therapeutics, Inc
Layout table for investigator information
Study Director: Javier Avendaño, MD Medical Director
Layout table for additonal information
Responsible Party: Stoke Therapeutics, Inc Identifier: NCT04740476    
Other Study ID Numbers: STK-001-DS-501
First Posted: February 5, 2021    Key Record Dates
Last Update Posted: February 10, 2023
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Stoke Therapeutics, Inc:
Pediatric epilepsy
Epileptic Encephalopathies
Refractory Myoclonic Epilepsy
Severe Myoclonic Epilepsy in Infancy
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Myoclonic
Pathologic Processes
Epilepsy, Generalized
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes